Scotiabank Maintains Outperform on Eli Lilly (LLY) Feb 2026, PT $1,300

Scotiabank maintained an Outperform rating on Eli Lilly and Company (LLY) on February 5, 2026, while raising its price target to $1,300. The firm issued the note at 10:43 AM and left the formal rating unchanged as Outperform, citing strong drug pipeline momentum. This LLY analyst rating update signals confidence from a major bank despite a recent share pullback of -1.93% or $-19.79 since the noted price point. Meyka AI, our AI-powered market analysis platform, tracks this action as part of real-time analyst coverage

LLY analyst rating: Scotiabank action and price target details

On Feb 05, 2026 at 10:43 AM, Scotiabank maintained Outperform on Eli Lilly and Company (LLY) and raised its price target from $1,165 to $1,300. The note was published by TheFly and flagged stronger revenue and pipeline visibility as the reasons source.

LLY analyst rating meaning: what maintained Outperform implies for investors

A maintained Outperform means Scotiabank expects LLY to exceed sector returns but kept conviction steady. Investors should view the move as reaffirmation, not a fresh buy signal, and weigh it against valuation and portfolio goals.

LLY analyst rating and price reaction: short-term market impact

Shares showed a -1.93% move since the note, equal to $-19.79 in the referenced window. Short-term price moves can reflect profit taking or broader market flows, not always analyst credibility.

LLY analyst rating history: context of analyst coverage

Scotiabank’s maintained Outperform joins a long history of bullish coverage from major houses that track Eli Lilly and Company. Historical coverage has often paired Outperform or Buy calls with progressive price target lifts as drug approvals and sales beat estimates.

LLY analyst rating: implications relative to market and peers

With a market capitalization of $914,798,261,228, Eli Lilly sits among large-cap pharma leaders. Investors comparing peers should consider pipeline durability, margin trends, and recent analyst price target changes when sizing positions.

LLY analyst rating and Meyka view: grade and investor guidance

Meyka AI rates LLY with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. We advise investors to treat the grade as one input, not as financial advice.

Final Thoughts

Scotiabank’s maintained Outperform on Eli Lilly and Company (LLY) on February 5, 2026, paired with a raised price target to $1,300, is a notable affirmation from a major analyst. The firm did not change the rating, so the update is more about a higher valuation thesis than a shift in conviction. For investors, the update reinforces bullish expectations for pipeline and revenue, but short-term price reaction of -1.93% shows market direction can differ from analyst tone. Meyka AI rates LLY with a grade of B+, reflecting strong fundamentals relative to peers, healthy growth expectations, and positive analyst sentiment. Use the LLY analyst rating alongside valuation metrics, downside risk, and position sizing rules. Remember our grade is informational and not investment advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.